Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Heart and Blood Diseases

Rare Diseases

Syndrome

Lymphoma

Multiple Myeloma

Neoplasms, Plasma Cell

Leukemia

Leukemia, Lymphoid

Hematologic Neoplasms

Leukemia, Myeloid

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease

Preleukemia

Myelodysplastic Syndromes

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hematologic Diseases

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Bone Marrow Diseases

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Myeloproliferative Disorders

Chronic Graft Versus Host Disease

Lymphosarcoma

Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Diffuse Large B-Cell Lymphoma

Hodgkin Lymphoma

B-cell Lymphoma

Chronic Myeloproliferative Disorders

Antineoplastic Agents

All Drugs and Chemicals

Treosulfan

Antineoplastic Agents, Alkylating

Alkylating Agents

Treosulfan i.v.: 14 g/m²/d from day -6 to day -4

Treosulfan IV

Luciano LC Callegaro, Monitor

Stefania ST Trinca, Data Manager

Angelo Michele Carella, MD

Marzia Tricarico, DM

Nicola Cascavilla, MD

Alessandro Crotta, MD

Stefania Trinca

Jacopo Peccatori, MD

Anna Grassi, MD

Maria Luisa Ferrari, DM

Alessandro Rambaldi, MD

Enrico Morello, MD

Adriana Vacca, MD

Giorgio La Nasa, MD

Laura Bertolotti, Data Manager

Andrea Gallamini, MD

Liliana Calabrese, Data Manager

Giovanni Martinelli, MD

Paolo Di Bartolomei, MD

Alessandro Bonini, MD

Luigi Gugliotta, MD

Emilia Iannella, MD

Roberto Ricci

Roberto Foa, MD

Beatrice Pinazzi, MD

Ignazio Majolino, MD

Francesca Patriarca, MD

Michela Cerno, MD

Fabio FC Ciceri, MD

This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (SCT) in patients with haematological malignancies.

The aim is to demonstrate a clinical benefit compared with historical data on intravenous busulfan (BusulfexTM, BusilvexTM), the only drug so far registered in the indication conditioning before allogeneic stem cell transplantation.

Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)

Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies

IRCCS San Raffaele

Fabio Ciceri, MD

Spots Global Cancer Trial Database for treosulfan iv